More than 400 cartons of Nilotinib capsules were voluntarily recalled by Cipla USA after failing manufacturing specifications ...
A US-based subsidiary of drugmaker Cipla is recalling over 400 cartons of generic anti-cancer medication due to a ...
In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...
Ipsen said it will now pull Tazverik from the market in all countries where it has rights to the first-in-class, chemotherapy ...
Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...
TD Cowen 46th Annual Health Care Conference March 4, 2026 10:30 AM ESTCompany ParticipantsBrian Sullivan - Co-Founder, Chairman ...
LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 –– Reduced secured and convertible debt by 90% from ...
HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
Women and girls bear the brunt of collapsing healthcare and mass displacement Medical staff describe an exponential rise in maternal and neo-natal health ...
A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...
Rising NEC Incidence: The global increase in diagnosed cases of neuroendocrine tumors (including carcinomas) is a major market growth driver. This uptick is driven by better detection and reporting, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results